Xenetic Biosciences (XBIO)
NASDAQ:XBIO
Want to see XBIO full AI Analyst Report?
XBIO Stock Chart & Stats
$2.21
-$0.03(-0.75%)
At close: 4:00 PM EST
$2.21
-$0.03(-0.75%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous CloseN/A
Volume4.73K
Average Volume (3M)1.70M
Market Cap
$7.03M
Enterprise Value-$2.66M
Total Cash (Recent Filing)$7.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap-0.38
Enterprise Value/Revenue-0.89
Enterprise Value/Gross Profit-0.89
Enterprise Value/Ebitda0.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Debt-light Balance SheetA near-zero debt position materially reduces refinancing and interest-rate risk, giving management optionality to fund R&D via equity, partnerships, or non-debt instruments. Over 2–6 months a debt-light capital structure lowers solvency risk and preserves flexibility for strategic choices.
Revenue Re-accelerationRe-accelerating top-line growth signals improving commercial traction or progress in development-related revenue streams. Sustained revenue momentum supports scaling potential and can reduce future funding pressure if continued, making the company's path to larger scale more credible over the medium term.
Improving Cash Burn TrendSequential improvement in cash burn indicates better cost discipline or revenue mix changes, helping extend runway and lowering near-term dilution risk. While still negative, a durable trend toward reduced burn increases the company's ability to fund operations with fewer immediate capital raises.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the company cannot self-fund operations and remains dependent on external financing. Over a 2–6 month horizon this structural cash burn creates funding risk and can force dilutive financings or restrict R&D/program timelines if market access tightens.
Ongoing Net Losses And Wide Negative MarginsPersistently large net losses and very negative margins indicate the business has not reached sustainable operating scale. This structural unprofitability erodes equity, pressures returns, and makes long-term viability contingent on successful pipeline commercialization or material margin improvement.
Governance / Shareholder Engagement RiskAdjourned annual meetings and low quorum reflect governance and engagement weaknesses that can delay corporate decisions, fundraising approvals, or board changes. These structural governance frictions raise execution risk and can impede timely strategic actions over the medium term.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $7.03M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 102 days.
How were Xenetic Biosciences’s earnings last quarter?
Currently, no data Available
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
4.36% Insiders
0.87% Mutual Funds
<0.01% Other Institutional Investors
94.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---